In addition, siltuximab, a monoclonal antibody targeting IL-6, was used to treat idiopathic multicentric Castleman disease (iMCD) (53) and cytokine release syndrome (CRS) associated with T-cell redirecting bispecific antibody therapy for relapsed/refractory multiple myeloma (RRMM) (54). Here, IL6 is linked to plasma cell myeloma.